Purpose of review: Elevated levels of low-density lipoprotein cholesterol (LDL-C) are causal to atherosclerosis and, thus, the reduction of LDL-C represents a major objective for the prevention of cardiovascular disease. Aim of this review is to provide an overview on novel strategies to lower LDL-C. Recent findings: Although inhibiting liver cholesterol biosynthesis by statins is used as the main therapeutic approach to increase hepatic LDL-receptor expression and lower plasma cholesterol levels, novel insights into lipid and lipoprotein biology have led to the development of additional lipid-lowering therapies that can be used in combination with or as an alternative to statins in patients with statin-intolerance. New approaches include bempedoic acid, proprotein convertase subtilisin/kexin type 9 inhibitors, and angiopoietin-like protein 3 inhibitors. Summary: In the last decade, several novel therapeutic approaches have been tested and some of them have been approved as lipid-lowering agents. Some drugs are already available in clinical practice, whereas others are at late stages of development.
Recent insights into low-density lipoprotein metabolism and therapy / A. Pirillo, A.L. Catapano, G.D. Norata. - In: CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE. - ISSN 1363-1950. - 24:2(2021 Mar 01), pp. 120-126.
|Titolo:||Recent insights into low-density lipoprotein metabolism and therapy|
NORATA, GIUSEPPE DANILO (Corresponding)
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||1-mar-2021|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1097/MCO.0000000000000727|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|2021-Curr Opin Clin Nutr Metab Care-Recent insights into LDL metabolism and therapy.pdf||Publisher's version/PDF||Administrator Richiedi una copia|